Panelists discuss how the greatest unmet needs include addressing poor outcomes in specific subsets like TP53-mutant disease, ...

Health care providers now recognize that determining treatment intensity requires careful evaluation of multiple patient factors beyond chronological age, including physiologic function, social ...

Results of a recently published long-term follow-up of the ASAP trial, which was conducted at universities and clinics across ...

City of Hope® Research Spotlight offers a glimpse into groundbreaking scientific and clinical discoveries advancing lifesaving cures for patients with cancer, diabetes and other chronic, ...

The selection of patients for allo-HSCT and the best approach to bridging patients to transplantation is continuously ...

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the best stocks to buy under $20. On September 19, Syndax Pharmaceuticals ...

Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial. Blood 2025 Jul 30:blood.2025028730. doi: 10.1182/blood.2025028730 Online ahead of ...

Approximately 60% to 70% of patients aged 18 to 65 years will achieve a complete remission, but just 30.5% of these patients ...

PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2025 AND KEY EVENTS DURING THE PERIOD Financial and ...

Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhibitors in frontline ...

Ziftomenib showed significant efficacy in relapsed/refractory NPM1-mutant AML, achieving deep, durable responses in the KOMET-001 trial. The trial enrolled 92 patients, with 23% achieving complete ...

Researchers used an 8-protein prognostic score termed the leukemia inflammatory risk score (LIRS) to identify inflammatory proteins with newly diagnosed AML.